Cargando…
Development of new TB regimens: Harmonizing trial design, product registration requirements, and public health guidance
Christian Lienhardt and colleagues discuss the importance of communication and coordination between regulators, researchers, and policy makers to ensure tuberculosis trials provide high-quality evidence for policy decisions.
Autores principales: | Lienhardt, Christian, Vernon, Andrew A., Cavaleri, Marco, Nambiar, Sumati, Nahid, Payam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6730844/ https://www.ncbi.nlm.nih.gov/pubmed/31490921 http://dx.doi.org/10.1371/journal.pmed.1002915 |
Ejemplares similares
-
Advances in clinical trial design: Weaving tomorrow’s TB treatments
por: Lienhardt, Christian, et al.
Publicado: (2020) -
Advances in clinical trial design for development of new TB treatments: A call for innovation
por: Lienhardt, Christian, et al.
Publicado: (2019) -
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape
por: Phillips, Patrick P. J., et al.
Publicado: (2019) -
The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials
por: Vernon, Andrew, et al.
Publicado: (2019) -
Designing noninferiority tuberculosis treatment trials: Identifying practical advantages for drug regimens with acceptable effectiveness
por: Olliaro, Piero L., et al.
Publicado: (2019)